10-KPeriod: FY2023

INTUITIVE SURGICAL INC Annual Report, Year Ended Dec 31, 2023

Filed January 31, 2024For Securities:ISRG

Summary

Intuitive Surgical Inc. (ISRG) demonstrated robust financial performance in its 2023 fiscal year, reporting a 14% increase in total revenue to $7.1 billion. This growth was primarily driven by a strong 22% increase in instruments and accessories revenue, reflecting higher da Vinci procedure volumes, which rose 22% to approximately 2.3 million procedures. The company also saw a significant 129% surge in Ion procedures. Despite flat systems revenue, the installed base of da Vinci systems grew by 14% to 8,606 units, indicating continued market penetration and utilization. The company's strategic focus on expanding its minimally invasive care ecosystem, including its Ion endoluminal system, and its commitment to innovation and customer training are key drivers of its success. While facing macroeconomic headwinds such as inflation and higher interest rates, which have impacted customer capital spending, ISRG has managed its operations effectively, maintaining a solid cash position and continuing to invest in research and development to drive future growth. The company's extensive risk factor disclosures highlight the competitive landscape, regulatory environment, and supply chain challenges as areas of ongoing attention.

Financial Highlights

47 data points
Beta

Revenue

$7.12B

66.4% Gross Margin

Net Income

$1.80B

25.2% Net Margin

EPS (Diluted)

$5.03

Total Assets

$15.44B

Cash & Equivalents

$2.77B

Free Cash Flow

$1.81B

Financial Statements
Beta
Revenue$7.12B
Cost of Revenue$2.39B
Gross Profit$4.73B
R&D Expenses$998.80M
SG&A Expenses$1.96B
Operating Expenses$2.96B
Operating Income$1.77B
Net Income$1.80B
EPS (Basic)$5.12
EPS (Diluted)$5.03
Shares Outstanding (Basic)351.20M
Shares Outstanding (Diluted)357.40M

Key Highlights

  • 1Total revenue increased by 14% to $7.1 billion in FY2023, driven by strong procedural growth.
  • 2Instruments and accessories revenue grew 22% to $4.28 billion, outperforming system revenue.
  • 3Da Vinci procedure volumes increased by 22% to approximately 2.3 million in FY2023.
  • 4Ion system procedures saw a substantial increase of 129%, reaching approximately 54,000 procedures.
  • 5The installed base of da Vinci surgical systems expanded by 14% to 8,606 units.
  • 6Systems revenue remained flat year-over-year at $1.68 billion, impacted by leasing arrangements and pricing.
  • 7The company maintained a strong liquidity position with $7.34 billion in cash, cash equivalents, and investments as of December 31, 2023.

Frequently Asked Questions

Intuitive Surgical's revenue growth in 2023 was primarily driven by a significant increase in instruments and accessories revenue (up 22%), which was fueled by a 22% rise in da Vinci procedure volumes and higher pricing. The company also experienced substantial growth in its Ion system procedures (up 129%) and a 14% increase in service revenue, supported by the expanding installed base of da Vinci systems.

Intuitive Surgical placed 1,370 da Vinci surgical systems in 2023, an 8% increase compared to 2022, indicating sustained demand for its core robotic systems. The installed base of da Vinci systems grew by 14% to 8,606 units. However, system revenue remained flat year-over-year due to factors like a higher proportion of systems placed under operating leases, lower average selling prices, and fewer third-generation trade-ins.

The company faces several risks, including intense competition from existing and emerging players in the robotic surgery market, macroeconomic conditions such as inflation and higher interest rates impacting customer spending, disruptions to its supply chain, reliance on sole- and single-sourced suppliers, and complex international regulatory environments. Additionally, litigation, potential product liability claims, and the need for continued market acceptance and physician training for its technologies are ongoing concerns.

Intuitive Surgical is committed to advancing minimally invasive care through a comprehensive ecosystem of products and services. This includes its advanced da Vinci surgical systems, the Ion endoluminal system for diagnostic procedures, a range of instruments and accessories, and robust learning and digital solutions. The company emphasizes investing in research and development to enhance existing products and develop new technologies, aligning its offerings with the Quadruple Aim of improving patient outcomes, patient experience, care team satisfaction, and reducing the total cost to treat per patient episode.